<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01612221</url>
  </required_header>
  <id_info>
    <org_study_id>HCI50308</org_study_id>
    <nct_id>NCT01612221</nct_id>
  </id_info>
  <brief_title>Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo</brief_title>
  <official_title>A Phase II Placebo-controlled Intervention Trial of Oral N-acetylcysteine (NAC) for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II intervention to propose a new melanoma chemoprevention agent. The
      investigators believe oxidative stress/damage in nevi is a probable indication for melanoma
      risk, and propose that reduced melanoma risk in humans can be inferred by protection of nevi
      from ultraviolet light (UV)-induced oxidative changes. The investigators will 1) evaluate
      whether administration of NAC around the time of UV exposure will reduce melanoma risk in
      high-risk patient populations with genetic susceptibility to UV-induced oxidative stress, and
      2) examine key genetic variants that will identify which individuals are most likely to
      benefit from chemoprotection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>UV-induced Oxidative Stress in Irradiated and Unirradiated Nevi</measure>
    <time_frame>3.5 years</time_frame>
    <description>Differences in the median percent nevus with 8-OG expression in UV-irradiated nevi compares with unirradiated nevi.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transcriptional Markers of UV-induced Oxidative Stress in Nevi</measure>
    <time_frame>3.5 years</time_frame>
    <description>Biomarkers susceptible to UV-induced damage protected by NAC (N-acetylcysteine) in irradiated and unirradiated nevi</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Patients at Risk for Melanoma</condition>
  <arm_group>
    <arm_group_label>Patients receiving N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving NAC (N-acetylcysteine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants not receiving NAC (N-acetylcysteine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>N-acetylcysteine (NAC), 1200 mg Oral route 2 doses</description>
    <arm_group_label>Patients receiving N-acetylcysteine</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo arm</intervention_name>
    <description>Sterile normal saline, diluted into 25 cc tomato juice, orally, x 1 dose. Then repeated 24 hours later.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have at least 2 nevi (each &gt;6 mm diameter) not clinically suspicious for melanoma
             that can be biopsied.

          -  Must be able to receive informed consent and sign an approved consent form that
             conforms to federal and institutional guidelines.

        Exclusion Criteria:

          -  The patient is a minor (&lt; 18 years old).

          -  The patient cannot speak/understand English or Spanish. (NOTE: A Spanish consent form
             and certified interpreter can be made available if needed)

          -  The patient is pregnant. (NOTE: All female patients who have not had a hysterectomy
             and are not post-menopausal (i.e. post-menopausal for 1 year and not of child-bearing
             potential) will have a urine pregnancy test.)

          -  The patient is a prisoner, critically or mentally ill, or otherwise incapacitated or
             considered vulnerable.

          -  The patient has history of allergic reaction to NAC.

          -  The patient has history of severe asthma.

          -  The patient has been taking NAC or any other oral antioxidant.

          -  The patient has recent history (i.e., 3 months) of sunless tanning (tanning bed) or
             extensive sunburn.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Grossman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huntsman Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2012</study_first_posted>
  <results_first_submitted>March 7, 2017</results_first_submitted>
  <results_first_submitted_qc>June 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2017</results_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients Receiving N-acetylcysteine</title>
          <description>Patients receiving NAC (N-acetylcysteine)
N-acetylcysteine: N-acetylcysteine (NAC), 1200 mg Oral route 2 doses</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Participants not receiving NAC (N-acetylcysteine)
Placebo arm: Sterile normal saline, diluted into 25 cc tomato juice, orally, x 1 dose.
Then repeated 24 hours later.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients Receiving N-acetylcysteine</title>
          <description>Patients receiving NAC (N-acetylcysteine)
N-acetylcysteine: N-acetylcysteine (NAC), 1200 mg Oral route 2 doses</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Participants not receiving NAC (N-acetylcysteine)
Placebo arm: Sterile normal saline, diluted into 25 cc tomato juice, orally, x 1 dose.
Then repeated 24 hours later.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>UV-induced Oxidative Stress in Irradiated and Unirradiated Nevi</title>
        <description>Differences in the median percent nevus with 8-OG expression in UV-irradiated nevi compares with unirradiated nevi.</description>
        <time_frame>3.5 years</time_frame>
        <population>One subject with low-risk MC1R randomized to drug was excluded from both analyses because the lesions removed were seborrheic keratoses and not nevi, and 2 subjects (one high-risk MC1R randomized to drug and one low-risk MC1R randomized to placebo) were excluded from analysis of 8-OG because there was insufficient tissue.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Receiving N-acetylcysteine</title>
            <description>Patients receiving NAC (N-acetylcysteine)
N-acetylcysteine: N-acetylcysteine (NAC), 1200 mg Oral route 2 doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants not receiving NAC (N-acetylcysteine)
Placebo arm: Sterile normal saline, diluted into 25 cc tomato juice, orally, x 1 dose.
Then repeated 24 hours later.</description>
          </group>
        </group_list>
        <measure>
          <title>UV-induced Oxidative Stress in Irradiated and Unirradiated Nevi</title>
          <description>Differences in the median percent nevus with 8-OG expression in UV-irradiated nevi compares with unirradiated nevi.</description>
          <population>One subject with low-risk MC1R randomized to drug was excluded from both analyses because the lesions removed were seborrheic keratoses and not nevi, and 2 subjects (one high-risk MC1R randomized to drug and one low-risk MC1R randomized to placebo) were excluded from analysis of 8-OG because there was insufficient tissue.</population>
          <units>percentage of 8-OG expression in nevi</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>UV Irradiated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.6" spread="12.3"/>
                    <measurement group_id="O2" value="96.2" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unirradiated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" spread="25.1"/>
                    <measurement group_id="O2" value="33.1" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.65</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transcriptional Markers of UV-induced Oxidative Stress in Nevi</title>
        <description>Biomarkers susceptible to UV-induced damage protected by NAC (N-acetylcysteine) in irradiated and unirradiated nevi</description>
        <time_frame>3.5 years</time_frame>
        <population>One subject with low-risk MC1R randomized to drug was excluded because the lesions removed were seborrheic keratoses and not nevi.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Receiving N-acetylcysteine</title>
            <description>Patients receiving NAC (N-acetylcysteine)
N-acetylcysteine: N-acetylcysteine (NAC), 1200 mg Oral route 2 doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Participants not receiving NAC (N-acetylcysteine)
Placebo arm: Sterile normal saline, diluted into 25 cc tomato juice, orally, x 1 dose.
Then repeated 24 hours later.</description>
          </group>
        </group_list>
        <measure>
          <title>Transcriptional Markers of UV-induced Oxidative Stress in Nevi</title>
          <description>Biomarkers susceptible to UV-induced damage protected by NAC (N-acetylcysteine) in irradiated and unirradiated nevi</description>
          <population>One subject with low-risk MC1R randomized to drug was excluded because the lesions removed were seborrheic keratoses and not nevi.</population>
          <units>markers of UV-induced oxidative stress</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GCLM Biomarker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.99" spread=".83"/>
                    <measurement group_id="O2" value="9.14" spread=".75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SLC1A4 Biomarker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.29" spread=".87"/>
                    <measurement group_id="O2" value="9.40" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SLC7A11 Biomarker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.73" spread="1.13"/>
                    <measurement group_id="O2" value="9.03" spread=".95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GCLM Biomarker analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SLC1A4 Biomarker analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.63</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SLC7A11 Biomarker analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.27</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Patients Receiving N-acetylcysteine</title>
          <description>Patients receiving NAC (N-acetylcysteine)
N-acetylcysteine: N-acetylcysteine (NAC), 1200 mg Oral route 2 doses</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Participants not receiving NAC (N-acetylcysteine)
Placebo arm: Sterile normal saline, diluted into 25 cc tomato juice, orally, x 1 dose.
Then repeated 24 hours later.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kimberlee Taylor</name_or_title>
      <organization>Huntsman Cancer Institute</organization>
      <phone>801-213-5673</phone>
      <email>Kimberlee.Taylor@hci.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

